BLOOD OR PLASMA TRANSFUSION FROM SURVIVORS
Another promising treatment option reviewed in this group's previous article was a transfusion of blood or plasma from convalescent Ebola survivors.[1] It is noteworthy to mention that whole-blood or plasma transfusion therapy was determined to be ethically acceptable by the WHO during the 2014-2015 outbreak, provided that certain risk-benefit elements are taken into consideration by the treating healthcare team.[60] Specific safety and ethical considerations include donor testing for EBOV RNA (must be negative on two independent blood draws conducted at least 48 h apart) and testing of the donated blood for donor-recipient compatibility and blood-borne infections. This general consideration also implies a requirement for facilities that are able to properly handle and process blood and blood products.[56] Donated blood may vary in protective efficacy because neutralizing antibodies may take several weeks to months to appear at sufficient levels.[56] Clinical research is underway to determine if there are benefits associated with such transfusion therapy in the setting of EBOV disease.[58]